TNF Inhibitor Prescribing For RA Nearly Doubles, Caremark Exec Says
Treatment regimens for the tumor necrosis factor-alpha inhibitors Abbott's Humira (adalimumab) and Johnson & Johnson's Remicade (infliximab) may be becoming increasingly aggressive
You may also be interested in...
FDA has upgraded the rheumatoid arthritis indication for J&J's Remicade (infliximab) to first-line use based on a trial in patients with early disease
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials